Big pharma, Biotech, Partnering, Pharma

Kyowa Hakko Kirin pharma deals Ultragenyx for KRN23 license

Posted on 06 September 2013

Tags: , , ,

Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23.

KRN23, the compound being licensed in the pharma deals, is a recombinant fully human monoclonal IgG1 antibody intended to treat X-linked hypophosphatemia.

KHK is currently completing a Phase 1/2 study in adults with XLH in the US and Canada, prior to these pharma deals.

The two companies plan to initiate a pediatric XLH program in 2014, as part of other pharma deals.

Related

Report: Partnering Deals and Alliances with Kyowa Hakko Kirin

Report: Monoclonal Antibodies Partnering Terms and Agreements

Report: Metabolic Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply